Culturing red blood cells from stem cells: a solution to present and future challenges of transfusion medicine?

  title={Culturing red blood cells from stem cells: a solution to present and future challenges of transfusion medicine?},
  author={Ghislain Rousseau and Christelle Mazurier and Luc Douay},
  journal={ISBT Science Series},
Transfusion needs are diversely fulfilled globally. Besides, with population ageing, the various problems faced by healthcare systems will become more and more prominent. As a consequence, the current model of blood supply has to be strengthened, and new sources of red blood cells (RBC) are welcome. A cell therapy approach, in which so‐called ‘cultured RBC’ (cRBC) are generated in vitro, might be a solution. We report here on the various obstacles that were overcome during the past decade to… 
2 Citations

Towards manufactured red blood cells for the treatment of inherited anemia

Recent progress in the erythroid culture field is discussed as well as opportunities for further scaling up of manufactured RBC production for transfusion practice.



Red blood cells from induced pluripotent stem cells: hurdles and developments

This review will focus on the recent findings about the generation of erythroid cells from induced pluripotent stem (iPS) cells and deals with the hurdles and next developments that will occur.

Ultra-high-yield manufacture of red blood cells from hematopoietic stem cells.

A robust ultra-high-yield RBC expansion process is successfully developed capable of producing over 500 units of RBC per UCB donation using fully defined culture medium and it is shown that RBC can be efficiently produced in agitated bioreactor systems, demonstrating that no fundamental barriers exist to the manufacture of R BC using large-scale approaches.

Prospects for the manufacture of red cells for transfusion

Red cell transfusion is an attractive goal for pluripotent stem cell‐derived therapeutics because it is a well‐characterised single cell suspension that lacks nucleated cells and has a low expression of human leucocyte antigen molecules, but many challenges remain in translating this cellular therapy to the clinic.

Large‐scale production of red blood cells from stem cells: What are the technical challenges ahead?

The current review sums up the main biological advances of the past decade, outlines the key biotechnological challenges for the large‐scale cost‐effective production of red blood cells, proposes solutions based on strategies used in the bioindustry and presents the state‐of‐the‐art of large-scale blood production.

Plasticity of Cells and Ex Vivo Production of Red Blood Cells

This result strongly suggests that immortalized human erythroid progenitor cell lines able to produce mature RBCs ex vivo can also be established.

Red blood cell generation from human induced pluripotent stem cells: perspectives for transfusion medicine

The complete differentiation of human induced pluripotent stem cells into definitive erythrocytes capable of maturation up to enucleated red blood cells containing fetal hemoglobin in a functional tetrameric form is reported for the first time.

Development of patient-specific hematopoietic stem and progenitor cell grafts from pluripotent stem cells, in vitro.

This review focuses on the current state of directed differentiation of pluripotent stem cells towards hematopoietic stem cells (HSCs), which are especially interesting because they are the longest known and, thus, most intensively investigated somatic stem cells.

Generation of red blood cells from human induced pluripotent stem cells.

The results demonstrate the feasibility of large-scale production of erythroid cells from fibroblast-derived hiPSCs, as has been described for hESCs, and it is shown that fibroblasts generated using lentivirus-based vectors and transgene-freehiPSCs generated using episomal vectors can be differentiated into RBCs with an efficiency similar to that of H1 h ESCs.